This report studies the Urology Drugs market. Urology drugs is the branch of drugs that focuses on diseases of the male and female urinary-tract system and the male reproductive organs.
Asia-Pacific Expected to Witness Fastest CAGR for the Urology Drugs Market

The global Urology Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Urology Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Urology Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Urology Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Urology Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Astellas
Endo
GP Pharm
Tolmar
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Α (alpha)-blockers
5 α-reductase inhibitors

Segment by Application
Hospital
Clinic
Others